CJC-1295 No DAC 5mg + Ipamorelin 5mg Pen

Price range: Rp1,900,000.00 through Rp2,500,000.00 ~$115.15–$151.52

CJC-1295 No DAC 5mg + Ipamorelin 5mg Pen combines two of the most popular recovery and performance-focused peptides into one convenient pre-mixed peptide pen designed for simplicity and convenience.

💉 Pre-Mixed Pen

⚡ No Mixing Required

💪 Recovery Support

🏋️ Gym User Favourite

🚚 Same-Day Bali Delivery

👨‍⚕️ Expert Guidance Included

10 Needles + 10 Alcohol pads included.
Description

CJC-1295 (No-DAC) + Ipamorelin Pen

Product Description

CJC-1295 (No-DAC) + Ipamorelin is a research peptide combination designed to investigate two complementary pathways involved in pulsatile growth hormone signalling.

CJC-1295 (No-DAC) acts as a synthetic analogue of growth hormone-releasing hormone (GHRH), while Ipamorelin acts primarily through the growth hormone secretagogue receptor (GHS-R1a), commonly associated with ghrelin signalling.

By targeting different receptors involved in growth hormone release, the combination is studied for its potential to influence the amplitude and pattern of endogenous GH secretion rather than supplying exogenous growth hormone directly. Pasted text

Research interest includes the GH/IGF-1 axis, recovery biology, body-composition signalling, collagen synthesis, connective-tissue biology, and metabolic regulation.

Atlas Longevity CJC-1295 (No-DAC) + Ipamorelin pens use the standard 3 mL cartridge / 300-click system and are available in two strengths:

  • 5 mg CJC-1295 (No-DAC) + 5 mg Ipamorelin
  • 5 mg CJC-1295 (No-DAC) + 10 mg Ipamorelin

These compounds remain investigational and are not established as approved therapeutic treatments.


Clinical / Research Status

The supplied reference describes both CJC-1295-related and Ipamorelin research spanning human, animal, observational, and laboratory evidence.

However, the strength of evidence is not equal across all proposed uses, and the supplied information does not establish regulatory approval for this combination as a therapeutic treatment. Pasted text

Evidence Type Status Based on Supplied Material
Human clinical research Yes
Observational research Yes
Animal research Yes
In-vitro research Yes
Approved therapeutic use Not established

The reference also lists a regulatory document concerning the combination, but the existence of regulatory documentation should not be confused with therapeutic approval. Pasted text


Evidence Type

The supplied material discusses:

  • human research involving growth-hormone-releasing hormone analogues;
  • human safety research;
  • growth hormone and IGF-1 measurements;
  • animal metabolic models;
  • pituitary-cell research;
  • somatotroph laboratory models;
  • comparative growth hormone secretagogue studies;
  • pharmacodynamic and mechanistic research.

Some cited research concerns the individual components or related CJC-1295 formulations rather than necessarily the exact Atlas CJC-1295 (No-DAC) + Ipamorelin combination.

For this reason, findings should be interpreted according to the compound, formulation, and study model actually investigated.


Mechanism of Action

CJC-1295 (No-DAC)

CJC-1295 (No-DAC) is designed to interact with GHRH receptors on pituitary somatotroph cells.

Activation of these receptors can stimulate growth hormone synthesis and release while remaining connected to endogenous hypothalamic-pituitary signalling.

The No-DAC formulation is intended for research into shorter-duration, pulsatile signalling rather than prolonged exposure.

Ipamorelin

Ipamorelin is a selective growth hormone secretagogue that acts primarily through the GHS-R1a receptor.

Activation of this receptor can stimulate intracellular signalling that promotes growth hormone release.

The supplied material describes Ipamorelin as being studied for relatively selective GH stimulation compared with secretagogues that can have broader endocrine effects. Pasted text

Dual-Pathway Research

When the two compounds are investigated together, the scientific rationale is that they stimulate growth hormone release through different but complementary receptor systems.

Researchers therefore examine whether simultaneous GHRH-receptor and GHS-R1a signalling can influence GH pulse amplitude, downstream IGF-1 signalling, metabolism, and regenerative pathways.

This mechanism does not establish guaranteed clinical effects in humans.


Potential Benefits / Research Areas

Growth Hormone Pulsatility Research

One of the principal areas of interest is the combination’s influence on endogenous growth hormone secretion.

Rather than acting as growth hormone itself, the compounds are studied as signalling molecules that may influence the body’s own GH-release pathways.

The supplied source describes increased GH signalling and downstream IGF-1 activity as central areas of investigation. Pasted text

Muscle Recovery Research

The GH/IGF-1 system participates in protein metabolism, tissue repair, and skeletal-muscle biology.

Experimental research involving growth hormone secretagogues has therefore examined markers related to:

  • muscle-fibre repair;
  • protein synthesis;
  • nitrogen metabolism;
  • satellite-cell activity;
  • recovery following physical stress.

The supplied source discusses these mechanisms, but they should not be interpreted as proof of predictable muscle gain in humans. Pasted text

Metabolic and Adipose-Tissue Research

Growth hormone signalling can influence lipid mobilisation and energy metabolism.

For this reason, CJC-1295 (No-DAC) + Ipamorelin research includes investigation of:

  • lipolysis;
  • fatty-acid mobilisation;
  • adipose-tissue metabolism;
  • body-composition signalling;
  • metabolic fuel utilisation. Pasted text

These mechanisms do not establish the combination as an approved weight-loss treatment.

Collagen and Connective-Tissue Research

The GH/IGF-1 pathway is involved in collagen metabolism and connective-tissue biology.

Research interest therefore includes potential effects on:

  • collagen production;
  • tendon and ligament biology;
  • skin extracellular matrix;
  • connective-tissue recovery;
  • musculoskeletal regeneration.

The supplied reference discusses collagen and tissue-repair effects, although clinical outcomes for specific injuries are not established. Pasted text

Bone Metabolism Research

Growth hormone and IGF-1 signalling interact with bone remodelling and osteoblast activity.

The combination is therefore of experimental interest in studies examining bone metabolism, mineralisation, and age-related changes in musculoskeletal biology.

This research area should not be interpreted as evidence that the combination treats osteoporosis or other bone disorders.

Sleep and Circadian GH Research

Growth hormone secretion naturally follows a pulsatile pattern, with substantial secretion associated with sleep.

The supplied source discusses the combination in relation to nocturnal GH secretion and sleep-associated recovery processes. Pasted text

However, the evidence supplied is not sufficient to present improved sleep quality as a guaranteed clinical benefit.

Regenerative and Recovery Research

Growth hormone and IGF-1 participate in multiple pathways related to cellular repair.

Researchers therefore investigate GH secretagogues in models involving:

  • muscle recovery;
  • collagen synthesis;
  • tissue remodelling;
  • physical stress;
  • connective-tissue repair.

Human therapeutic recovery claims cannot be established from these mechanisms alone.

Endocrine Rhythm Research

The No-DAC formulation is of particular interest in research focused on pulsatile rather than continuously elevated GH signalling.

This makes the combination relevant to studies examining the timing, amplitude, and physiological pattern of pituitary growth hormone release.


Research Data

Study / Model Reported Finding
Rat pituitary-cell assays Increased GH release following GHRH-receptor stimulation
Human GH-related research described by source Increased GH and IGF-1 measurements were reported
Preclinical metabolic models Changes in fat mass, lean tissue and GH-mediated metabolic signalling
Aged rodent models Changes in collagen synthesis and muscle-fibre repair
Comparative GHRP research Ipamorelin showed relatively limited cortisol response compared with some other GHRPs
In-vitro somatotroph models Dual-receptor signalling increased GH-related secretory responses

The source includes both human and preclinical research, but findings from animal or cellular studies should not be presented as established human outcomes. Pasted text


Potential Stack / Combination Research

The supplied reference discusses experimental research concepts combining CJC-1295 (No-DAC) + Ipamorelin with:

  • GHK-Cu;
  • BPC-157 and TB-500;
  • NAD+;
  • MOTS-c. Pasted text

The theoretical rationale involves complementary pathways related to tissue repair, mitochondrial metabolism, cellular energy, and recovery biology.

However, the supplied material does not establish validated human safety, compatibility, efficacy, or optimal dosing for these combinations.

They should therefore be treated as experimental research concepts rather than recommended stacks.


Atlas Longevity CJC-1295 (No-DAC) + Ipamorelin Pen Dosage / Click Chart

Atlas Longevity pens contain:

3 mL total volume

300 total clicks

1 click = 0.01 mL

Maximum selectable dial amount = 60 clicks

Two concentration variants are described below.


5 mg CJC-1295 (No-DAC) + 5 mg Ipamorelin Pen

This pen contains:

  • 5 mg CJC-1295 (No-DAC)
  • 5 mg Ipamorelin
  • 10 mg combined peptide content
Pen Strength Volume Total Concentration Total Amount Per Click
5 mg + 5 mg 3 mL ≈3.333 mg/mL ≈0.0333 mg

Individual Compound Concentrations

CJC-1295 (No-DAC):

5 mg ÷ 3 mL = ≈1.667 mg/mL

5 mg ÷ 300 = ≈0.0167 mg / 16.7 mcg per click

Ipamorelin:

5 mg ÷ 3 mL = ≈1.667 mg/mL

5 mg ÷ 300 = ≈0.0167 mg / 16.7 mcg per click

Therefore:

1 click ≈ 16.7 mcg CJC-1295 + 16.7 mcg Ipamorelin

Total ≈33.3 mcg per click

5 mg + 5 mg Click Conversion

Clicks Volume CJC-1295 Ipamorelin Total Peptide
1 0.01 mL ≈0.0167 mg ≈0.0167 mg ≈0.0333 mg
5 0.05 mL ≈0.0833 mg ≈0.0833 mg ≈0.1667 mg
10 0.10 mL ≈0.1667 mg ≈0.1667 mg ≈0.3333 mg
15 0.15 mL 0.250 mg 0.250 mg 0.500 mg
20 0.20 mL ≈0.3333 mg ≈0.3333 mg ≈0.6667 mg
30 0.30 mL 0.500 mg 0.500 mg 1.000 mg
40 0.40 mL ≈0.6667 mg ≈0.6667 mg ≈1.333 mg
45 0.45 mL 0.750 mg 0.750 mg 1.500 mg
50 0.50 mL ≈0.8333 mg ≈0.8333 mg ≈1.667 mg
60 0.60 mL 1.000 mg 1.000 mg 2.000 mg

5 mg CJC-1295 (No-DAC) + 10 mg Ipamorelin Pen

This variant contains:

  • 5 mg CJC-1295 (No-DAC)
  • 10 mg Ipamorelin
  • 15 mg combined peptide content
Pen Strength Volume Total Concentration Total Amount Per Click
5 mg + 10 mg 3 mL 5 mg/mL 0.05 mg

Individual Compound Concentrations

CJC-1295 (No-DAC):

5 mg ÷ 3 mL = ≈1.667 mg/mL

5 mg ÷ 300 = ≈0.0167 mg / 16.7 mcg per click

Ipamorelin:

10 mg ÷ 3 mL = ≈3.333 mg/mL

10 mg ÷ 300 = ≈0.0333 mg / 33.3 mcg per click

Therefore:

1 click ≈16.7 mcg CJC-1295 + 33.3 mcg Ipamorelin

Total = 50 mcg per click

5 mg + 10 mg Click Conversion

Clicks Volume CJC-1295 Ipamorelin Total Peptide
1 0.01 mL ≈0.0167 mg ≈0.0333 mg 0.050 mg
5 0.05 mL ≈0.0833 mg ≈0.1667 mg 0.250 mg
10 0.10 mL ≈0.1667 mg ≈0.3333 mg 0.500 mg
15 0.15 mL 0.250 mg 0.500 mg 0.750 mg
20 0.20 mL ≈0.3333 mg ≈0.6667 mg 1.000 mg
30 0.30 mL 0.500 mg 1.000 mg 1.500 mg
40 0.40 mL ≈0.6667 mg ≈1.333 mg 2.000 mg
50 0.50 mL ≈0.8333 mg ≈1.667 mg 2.500 mg
60 0.60 mL 1.000 mg 2.000 mg 3.000 mg

The 60-click maximum is a mechanical pen limit, not a recommended amount.


Protocol / Dosage Information

The original source describes experimental total quantities of approximately 0.75 mg, 1 mg, and 1.5 mg in its proposed research protocols. Pasted text

Those source calculations were based on a different 2 mL pen configuration, so they cannot be copied into the Atlas 3 mL / 300-click system.

The correct Atlas mathematical conversions are:

Source-Referenced Total Amount 5 mg + 5 mg Atlas Pen 5 mg + 10 mg Atlas Pen
0.75 mg total ≈22.5 clicks* 15 clicks
1.00 mg total 30 clicks 20 clicks
1.50 mg total 45 clicks 30 clicks

*A 22.5-click setting is not selectable as an exact whole click. Therefore, 0.75 mg total cannot be dialled exactly on the 5 mg + 5 mg Atlas pen.

These figures are provided only to translate the quantities described in the supplied material into the Atlas pen concentration.

They are not established medical dosing recommendations.

The supplied information does not establish an approved human treatment dose, treatment duration, cycling schedule, or clinical protocol for this peptide combination.


Possible Side Effects

The supplied reference describes several effects that may occur in research involving compounds that increase GH signalling, including:

  • injection-site redness, irritation, pain, or swelling;
  • temporary fluid retention;
  • headache;
  • flushing;
  • tingling or numbness;
  • dizziness. Pasted text

Because changes in GH and IGF-1 signalling can have systemic effects, a complete safety profile should not be inferred from statements that the compounds were “well tolerated.”

The supplied information does not establish all potential:

  • long-term adverse effects;
  • endocrine consequences;
  • metabolic effects;
  • contraindications;
  • drug interactions;
  • reproductive risks;
  • combination-related risks.

Product Attributes

Attribute CJC-1295 (No-DAC) Ipamorelin
CAS Number 863288-34-0 170851-70-4
Molecular Formula C152H252N44O42 C38H49N9O5
Molecular Weight listed by source ≈3367.9 g/mol ≈711.9 g/mol
PubChem CID 91976842 9831659
Half-Life listed by source ≈30 minutes ≈2 hours
Compound Type Synthetic GHRH analogue Synthetic growth hormone secretagogue peptide
Primary Research Pathway GHRH receptor signalling GHS-R1a / ghrelin-receptor signalling

The supplied reference also lists peptide sequences and several synonyms for the individual compounds. Pasted text

Because peptide identity and chemical specifications can vary by exact analogue or salt form, final Atlas product specifications should be matched against the corresponding product COA before publication where required.

Included in the Box

Each Atlas Longevity product is carefully packed to support secure storage, clean handling, and convenient research use. Inside the package, you’ll find the essential items needed for organized laboratory handling:

  • 1× Ready-to-Use Injection Pen
  • 10× Ultra-Fine Needles (33G, 4 mm)
  • 10× Alcohol Prep Pads
  • Protective Foam Insert to help keep the pen secure during transport
  • Quick-Reference Instruction Panel inside the packaging
  • Tamper-Evident Security Seal for added package protection

Each component is arranged in a clean, protective presentation designed to keep the product secure and easy to access.

Storage

Storage conditions should follow the instructions supplied with the specific Atlas Longevity CJC-1295 (No-DAC) + Ipamorelin formulation.

The reference source provides refrigeration and stability instructions for its own pre-mixed product, but those conditions should not automatically be transferred to an Atlas Longevity formulation without product-specific stability confirmation.

Follow the storage temperature, light-protection requirements, shelf-life information, and handling instructions printed on the Atlas Longevity product label or accompanying documentation.

 


Frequently Asked Questions

What is CJC-1295 (No-DAC) + Ipamorelin?

CJC-1295 (No-DAC) + Ipamorelin is a research peptide combination investigated for its effects on endogenous growth hormone signalling.

CJC-1295 (No-DAC) primarily acts through GHRH-related signalling, while Ipamorelin acts through the growth hormone secretagogue receptor.


How does CJC-1295 (No-DAC) + Ipamorelin work?

The compounds stimulate separate receptor pathways involved in growth hormone release.

CJC-1295 (No-DAC) activates GHRH receptors, while Ipamorelin primarily activates GHS-R1a receptors.

Researchers study the combination to understand whether dual-pathway stimulation can modify the timing or amplitude of GH release. Pasted text


What does “No-DAC” mean?

Within the supplied reference, the No-DAC form is described as a shorter-acting approach intended to produce more transient growth-hormone signalling rather than the prolonged activity associated with DAC-containing versions.


Is CJC-1295 (No-DAC) + Ipamorelin the same as growth hormone?

No.

Neither compound is human growth hormone itself.

They are researched for their ability to stimulate signalling pathways involved in the body’s endogenous release of growth hormone.


What is CJC-1295 (No-DAC) + Ipamorelin researched for?

Research areas described in the supplied material include:

  • GH and IGF-1 signalling;
  • endocrine pulsatility;
  • muscle-recovery biology;
  • collagen metabolism;
  • connective-tissue research;
  • adipose metabolism;
  • body-composition signalling;
  • metabolic regulation;
  • regenerative research.

Not all of these areas have the same level of clinical evidence.


How much product is in the 5 mg + 5 mg Atlas Longevity pen?

The pen contains:

5 mg CJC-1295 (No-DAC)

plus:

5 mg Ipamorelin

for:

10 mg total peptide content in 3 mL.


How much product is in the 5 mg + 10 mg pen?

The pen contains:

5 mg CJC-1295 (No-DAC)

plus:

10 mg Ipamorelin

for:

15 mg total peptide content in 3 mL.


How many clicks are in each Atlas Longevity pen?

Each pen contains:

300 total clicks / units

and:

1 click = 0.01 mL


How much is one click of the 5 mg + 5 mg pen?

Each click contains approximately:

16.7 mcg CJC-1295 (No-DAC)

plus:

16.7 mcg Ipamorelin

for approximately:

33.3 mcg total peptide per click.


How much is one click of the 5 mg + 10 mg pen?

Each click contains approximately:

16.7 mcg CJC-1295 (No-DAC)

plus:

33.3 mcg Ipamorelin

for:

50 mcg total peptide per click.


How many clicks equal 0.5 mg total?

For the 5 mg + 5 mg pen:

15 clicks = 0.5 mg total

consisting of:

0.25 mg CJC-1295 + 0.25 mg Ipamorelin

For the 5 mg + 10 mg pen:

10 clicks = 0.5 mg total

consisting of approximately:

0.167 mg CJC-1295 + 0.333 mg Ipamorelin

These are concentration calculations rather than dosing recommendations.


How many clicks equal 1 mg total?

For the 5 mg + 5 mg pen:

30 clicks = 1 mg total

For the 5 mg + 10 mg pen:

20 clicks = 1 mg total


What is the maximum selectable amount on the pen?

The Atlas pen allows a maximum selection of:

60 clicks = 0.60 mL

For the 5 mg + 5 mg pen, this equals:

1 mg CJC-1295 + 1 mg Ipamorelin = 2 mg total

For the 5 mg + 10 mg pen, this equals:

1 mg CJC-1295 + 2 mg Ipamorelin = 3 mg total

This is a mechanical concentration calculation, not a recommended amount.


How long does the pen last?

Each Atlas Longevity pen contains 300 clicks.

The number of administrations mathematically available is:

300 ÷ number of clicks used each time

For example:

  • 10 clicks at a time = 30 administrations
  • 15 clicks at a time = 20 administrations
  • 20 clicks at a time = 15 administrations
  • 30 clicks at a time = 10 administrations
  • 60 clicks at a time = 5 administrations

These examples describe cartridge capacity only.


Does the pen empty when the dial returns to zero?

No.

The dial returns to zero after administration, while the unused formulation remains inside the cartridge.

The remaining contents can continue to be selected until all 300 pen units have been used.


Have CJC-1295 and Ipamorelin been studied in humans?

The supplied reference identifies human research relating to growth hormone secretagogues and CJC-1295-related compounds alongside animal and laboratory research. Pasted text

However, evidence involving one component or another CJC formulation should not automatically be treated as clinical evidence for the exact CJC-1295 (No-DAC) + Ipamorelin combination.


Is CJC-1295 (No-DAC) + Ipamorelin approved for anti-ageing or muscle growth?

The supplied information does not establish regulatory therapeutic approval for those uses.

Research into GH, IGF-1, body composition, recovery, and ageing-related biology should not be interpreted as approval for treatment.


How should the pen be stored?

Follow the storage instructions supplied specifically with the Atlas Longevity formulation.

Although the reference product provides refrigeration instructions for its own pre-mixed pen, Atlas-specific temperature and stability claims should be based on the actual Atlas formulation rather than copied from another supplier.